Research quality Shop Now

Third-party tested peptides for laboratory research

NAD+ Research: Sirtuin Activation, Mitochondrial Function, and Cellular Energy Metabolism Studies

Research Use Only Disclaimer

All content on this page is intended for educational and informational purposes in the context of laboratory research only. NAD+ is a Research Use Only (RUO) compound. It is not approved for human or veterinary use, and nothing on this page constitutes medical advice, treatment guidance, or a therapeutic claim.

NAD+ Research: Sirtuin Activation, Mitochondrial Function, and Cellular Energy Metabolism Studies

Nicotinamide adenine dinucleotide is among the most intensively studied molecules in the longevity, metabolism, and cellular aging research landscape. Across decades of preclinical literature and a growing base of translational study findings, NAD+ has emerged not just as a coenzyme involved in cellular energy production but as a central regulatory molecule whose tissue-level concentration appears to govern a wide network of biological processes including sirtuin-dependent gene regulation, mitochondrial quality control, DNA repair capacity, and cellular senescence progression.

The reason NAD+ has moved from biochemistry textbook material into active longevity and metabolic aging research is a straightforward but consequential observation: NAD+ tissue levels decline substantially with age across multiple organs and species, and this decline correlates temporally and functionally with the onset of mitochondrial dysfunction, impaired DNA repair, and the accumulation of senescent cells that are now recognized as defining features of biological aging.

For research programs investigating cellular aging, metabolic disease, mitochondrial biology, or sirtuin pharmacology, NAD+ is not simply a background molecule. It is a quantifiable, modulatable research target whose preclinical literature now spans thousands of peer-reviewed publications and continues to expand rapidly in 2025 and 2026. This article covers NAD+ research comprehensively: the biosynthesis and salvage pathways that govern its tissue availability, sirtuin activation mechanisms with a detailed look at SIRT1 and SIRT3, mitochondrial biogenesis and quality control findings, PARP-mediated DNA repair research, the cellular energy metabolism endpoints most studied in NAD+ preclinical protocols, and the companion compound research panels that are commonly used alongside NAD+ in longevity and metabolic aging study designs.

NAD+ Biosynthesis Pathways: How Cells Make and Recycle NAD+

Understanding NAD+ research begins with understanding how cells produce and maintain their NAD+ supply, because the biosynthesis and salvage pathway literature is directly relevant to the experimental models used in NAD+ research and to the interpretation of intervention study results.

The De Novo Synthesis Pathway

NAD+ is synthesized de novo from tryptophan through the kynurenine pathway, a multi-step enzymatic route that terminates in the production of nicotinic acid mononucleotide and then NAD+. A 2025 review published in npj Metabolic Health and Disease (Yusri K et al., doi:10.1038/s44324-025-00067-0) notes that de novo synthesis from tryptophan is restricted to the liver and kidneys in mammals, making these organs the primary sites of whole-body NAD+ production via this route and important tissues for NAD+ research model selection.

The Salvage Pathway and NAMPT

The dominant NAD+ biosynthesis route in most mammalian tissues is the salvage pathway, in which nicotinamide released by NAD+-consuming enzymes is recycled back to NAD+ through the action of nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting enzyme of the salvage pathway. NAMPT converts nicotinamide to nicotinamide mononucleotide (NMN), which is then converted to NAD+ by NMN adenylyltransferases (NMNATs). NAMPT activity and expression have been studied as upstream regulators of tissue NAD+ availability and as research targets for interventions aimed at restoring age-related NAD+ decline.

CD38 as a Primary NAD+ Consumer in Aging

The 2025 npj Metabolic Health and Disease review by Yusri K and colleagues identifies CD38, a membrane-bound NAD+ hydrolase expressed in immune cells and tissues throughout the body, as a major driver of the age-related NAD+ decline observed in rodent and human studies. CD38 expression increases substantially with age, and the resulting accelerated NAD+ hydrolysis is proposed as one of the principal mechanisms through which tissue NAD+ levels fall in aging organisms. Research designs investigating CD38 inhibition as a strategy to restore NAD+ in aged tissue have become a significant component of the NAD+ longevity research literature and represent an important point of mechanistic comparison with direct NAD+ precursor supplementation approaches.

The Preiss-Handler Pathway

A third biosynthesis route, the Preiss-Handler pathway, converts nicotinic acid (niacin) to NAD+ through nicotinic acid mononucleotide as an intermediate. This pathway is relevant to NAD+ research because nicotinic acid and its ribonucleotide precursor have been studied as NAD+ precursors in animal models, though nicotinic acid’s side-effect profile in rodent models has limited preclinical applications. Research comparing the relative NAD+-boosting efficacy of different precursor compounds entering via different biosynthesis routes is an active area of the NAD+ preclinical literature.

Sirtuin Activation Research: SIRT1 Through SIRT7

The sirtuin enzyme family is the most studied downstream effector pathway in NAD+ research, and its relevance to longevity, metabolic regulation, and mitochondrial function has driven much of the interest in NAD+ as a research tool compound in aging biology.

Sirtuins are NAD+-dependent deacylases: they cannot function without NAD+ as a cofactor, and their activity is therefore directly coupled to the cellular NAD+/NADH ratio. Seven mammalian sirtuins have been characterized (SIRT1 through SIRT7), each with distinct subcellular localizations, substrate preferences, and biological functions.

SIRT1 and Mitochondrial Biogenesis

SIRT1 is the most extensively studied sirtuin in NAD+ longevity research. It is a nuclear deacetylase whose primary mechanism in the mitochondrial biogenesis context is the deacetylation and activation of PGC-1 alpha (peroxisome proliferator-activated receptor gamma coactivator 1 alpha), the master transcriptional regulator of mitochondrial biogenesis. When NAD+ is sufficient and SIRT1 is active, PGC-1 alpha deacetylation drives the expression of genes encoding mitochondrial proteins, facilitating the generation of new mitochondria and the maintenance of mitochondrial mass and function in aging tissue. Age-related NAD+ decline therefore suppresses SIRT1 activity, reduces PGC-1 alpha deacetylation, and contributes to the loss of mitochondrial mass and function that characterizes aged skeletal muscle, cardiac muscle, liver, and neuronal tissue in rodent aging models.

SIRT1 and the AMPK/NAD+ Feedback Loop

SIRT1 research has also characterized a positive feedback relationship between SIRT1, AMPK (AMP-activated protein kinase), and NAMPT that amplifies the cellular response to low-energy states. AMPK activation increases NAMPT expression, which drives NAD+ synthesis, which activates SIRT1, which in turn activates AMPK through LKB1 deacetylation. This SIRT1-AMPK-NAMPT feedback loop is a key regulatory circuit studied in NAD+ cellular energy metabolism research and represents a mechanistic basis for the metabolic effects observed when NAD+ availability is experimentally manipulated in cell and animal research models.

SIRT3 and Mitochondrial Quality Control

SIRT3 is the principal NAD+-dependent deacetylase inside the mitochondrial matrix and has been the subject of substantial dedicated research interest as a regulator of mitochondrial protein acetylation status, oxidative metabolism efficiency, and the antioxidant defense systems within the mitochondrion.

A 2025 review published in Genes (Seslja K, Simunic E et al., doi:10.3390/genes16121497) provides a comprehensive analysis of SIRT3-mediated mitochondrial regulation in systemic aging, proposing the concept of “driver tissues” where SIRT3 loss initiates a cascade of senescent signaling that spreads to distant organs. The key SIRT3 substrates studied in this research include superoxide dismutase 2 (SOD2), isocitrate dehydrogenase 2 (IDH2), and the long-chain acyl-CoA dehydrogenase (LCAD) involved in fatty acid oxidation. When SIRT3 activity declines due to insufficient NAD+, these substrates become hyperacetylated, their enzymatic activity falls, mitochondrial ROS production rises, and the antioxidant capacity of the mitochondrial matrix is compromised.

SIRT3, FOXO3a, and Mitophagy

The Seslja et al. review also documents SIRT3-dependent regulation of mitophagy through FOXO3 alpha deacetylation. Active SIRT3 deacetylates FOXO3 alpha, enabling it to upregulate PINK1 and Parkin expression, which are the core mediators of ubiquitin-dependent mitophagy, the selective autophagic clearance of damaged mitochondria. The SIRT3-FOXO3a-PINK1/Parkin axis is one of the most studied mitochondrial quality control pathways in NAD+ research and provides a mechanistic link between NAD+ availability and the rate at which cells clear dysfunctional mitochondria, a process whose impairment is directly implicated in the inflammatory burden of aging tissue.

SIRT3 and the SASP Connection

The Genes 2025 paper further proposes that SIRT3 deficiency in “driver tissues” including liver, adipose tissue, vascular endothelium, and bone-marrow macrophages propagates senescence-associated secretory phenotype (SASP) signaling to distant organs through circulating cytokines, extracellular vesicles, and mitochondrial DNA. SOD2 hyperacetylation in SIRT3-deficient cells activates NF-kB and p38 MAPK signaling, which drives SASP gene expression. This proposed mechanism positions SIRT3, and by extension NAD+ availability, at the intersection of mitochondrial biology and the inflammaging hypothesis that links chronic low-grade inflammation to the age-associated decline in tissue function.

SIRT2 and Mitochondrial Dynamics

SIRT2 is a cytoplasmic sirtuin that influences mitochondrial morphology through regulation of the fusion-fission balance. Research reviewed in the 2025 npj Metabolic Health and Disease paper by Yusri K et al. documents that SIRT2 promotes mitochondrial fusion by increasing MFN2 (mitofusin 2) and reducing DRP1 (dynamin-related protein 1) activity. The balance of mitochondrial fusion and fission determines mitochondrial network morphology and is directly coupled to cellular metabolic state, making SIRT2 regulation of mitochondrial dynamics a relevant endpoint in NAD+ cellular energy metabolism research designs.

SIRT5 and Mitochondrial Metabolic Enzyme Regulation

SIRT5 is a mitochondrial sirtuin with a preference for removing succinyl, malonyl, and glutaryl groups from lysine residues rather than acetyl groups. Its substrates include enzymes in the urea cycle, fatty acid oxidation, and amino acid catabolism. SIRT5 research in the context of NAD+ biology is particularly relevant for metabolic disease research panels that examine how NAD+ depletion affects the efficiency of mitochondrial substrate oxidation beyond glucose and fatty acid metabolism.

Mitochondrial Function Research: Electron Transport Chain and Oxidative Phosphorylation

Beyond sirtuin-mediated regulation, NAD+ has a direct and immediate role in mitochondrial electron transport chain (ETC) function as the primary electron carrier feeding reducing equivalents into the ETC at Complex I.

NAD+/NADH Ratio and ETC Efficiency

NADH (the reduced form of NAD+) donates electrons to NADH dehydrogenase (Complex I) of the ETC, driving proton pumping and ATP synthesis through oxidative phosphorylation. The NAD+/NADH ratio is therefore a direct determinant of the substrate availability for oxidative phosphorylation. When NAD+ is depleted and the ratio falls, cells shift to less efficient fermentative metabolism, producing less ATP per unit of substrate oxidized and generating more lactate, a metabolic shift that is studied in the context of both aging biology and metabolic disease research.

Mitochondrial Biogenesis and PGC-1 Alpha Research

The SIRT1-PGC-1 alpha pathway described above represents the primary transcriptional control axis for mitochondrial biogenesis research in the NAD+ field. PGC-1 alpha, when deacetylated by SIRT1, co-activates nuclear respiratory factors (NRF1 and NRF2) and estrogen-related receptors (ERRs) to drive expression of the hundreds of genes needed for mitochondrial protein import, electron transport chain assembly, mtDNA replication, and mitochondrial membrane synthesis. Research in aged rodent models has demonstrated that restoring NAD+ availability re-engages the SIRT1-PGC-1 alpha axis and partially restores mitochondrial mass and function in skeletal muscle and liver, making this the most mechanistically documented pathway in NAD+ mitochondrial biogenesis research.

Mitochondrial Unfolded Protein Response

The mitochondrial unfolded protein response (UPRmt) is a stress-response pathway triggered when misfolded proteins accumulate in the mitochondrial matrix, and it is regulated in part through SIRT3-dependent mechanisms described in the 2025 Genes review. The UPRmt drives expression of mitochondrial chaperones and proteases that restore proteostasis within the organelle and is studied as a key quality control mechanism in longevity and aging model research. Its activation has been associated with extended lifespan in multiple model organisms, making it an important endpoint in NAD+ research designs that examine mitochondrial stress responses in aged tissue.

PARP DNA Repair Research and NAD+ Competition

Poly-ADP-ribose polymerases (PARPs) are NAD+-consuming enzymes whose primary function is the detection and repair of single- and double-strand DNA breaks through ADP-ribosylation of chromatin and repair scaffold proteins. PARP1 is the most studied member of the family and is among the largest consumers of cellular NAD+.

PARP1 Hyperactivation in Aging

Research in aged tissue and in cells exposed to genotoxic stress has documented that PARP1 hyperactivation, driven by the accumulation of unrepaired oxidative DNA lesions in aging cells, depletes NAD+ at a rate that outpaces the cell’s biosynthetic capacity, creating a competition between PARP-mediated DNA repair and sirtuin-dependent metabolism and gene regulation. This PARP-sirtuin NAD+ competition is a central mechanistic hypothesis in the NAD+ longevity research field: as DNA damage accumulates with age, PARP1 activation consumes the NAD+ that sirtuins need to maintain mitochondrial function and metabolic efficiency, driving a vicious cycle of declining energy metabolism, increased mitochondrial ROS, further DNA damage, and further PARP activation.

PARP and Genotoxic Stress Models

NAD+ preclinical research has used pharmacological PARP inhibition alongside NAD+ supplementation to disentangle the relative contributions of PARP hyperactivation and sirtuin downregulation to the metabolic phenotype of aged or genotoxically stressed tissue. These dual-intervention designs are among the more mechanistically informative approaches in NAD+ research because they allow investigators to attribute metabolic effects specifically to the sirtuin or PARP axis without confounding from the other major NAD+ consumption pathway.

Cellular Senescence and NAD+ Research

Cellular senescence, the state of stable cell cycle arrest combined with a pro-inflammatory SASP secretory program, has become one of the most studied endpoints in NAD+ aging biology research.

NAD+ Depletion and Senescence Induction

Research has documented that NAD+ depletion in cell culture systems is sufficient to induce markers of cellular senescence including p21 and p16 upregulation, SA-beta-galactosidase positivity, and SASP cytokine secretion. Conversely, restoration of NAD+ levels in pre-senescent or early-senescent cells in culture has been shown to delay or partially reverse these senescence markers in some experimental models. These cell culture findings provide a mechanistic framework for interpreting the in vivo NAD+ animal aging research and for designing experiments that test whether NAD+ restoration can reduce the senescent cell burden in aged tissue.

SIRT1 Regulation of the p53/p21 Axis

One of the most studied mechanistic links between NAD+-dependent SIRT1 activity and senescence regulation is the SIRT1-mediated deacetylation of p53, which reduces p53 transcriptional activity at the p21 promoter, thereby suppressing one of the primary drivers of cell cycle arrest in genotoxically stressed cells. This mechanism is directly relevant to NAD+ cellular aging research because it connects the NAD+/SIRT1 axis to the p53/p21 senescence program through a well-characterized deacetylation event that can be studied quantitatively in cell culture and animal model systems.

NAD+ Cellular Energy Metabolism Research

Beyond the specific sirtuin and PARP pathways, NAD+ research has examined its broader effects on cellular energy metabolism endpoints in aged and metabolically impaired tissue.

Glycolytic Efficiency and Lactate Production

The ratio of oxidative phosphorylation to glycolysis in metabolically active cells is directly coupled to NAD+ availability. Research in aged skeletal muscle, cardiac muscle, and hepatic tissue has documented a shift toward glycolytic metabolism with lower ATP yield per substrate molecule oxidized, consistent with the NAD+ depletion hypothesis. Measurement of the oxygen consumption rate (OCR) to extracellular acidification rate (ECAR) ratio using metabolic flux analysis (Seahorse assay) is among the standard endpoints used in NAD+ research to quantify this metabolic shift in vitro.

Fatty Acid Oxidation and LCAD

SIRT3-dependent activation of LCAD and other fatty acid oxidation enzymes makes NAD+ a direct regulator of mitochondrial beta-oxidation efficiency. Research in SIRT3 knockout mice and in models of NAD+ depletion has documented impaired fatty acid oxidation, increased triglyceride accumulation, and reduced ketone body production in hepatic tissue, findings that are mechanistically consistent with the SIRT3-LCAD deacetylation pathway and that are studied as metabolic endpoints in NAD+ research designs examining lipid metabolism.

ATP Production and Mitochondrial Membrane Potential

Mitochondrial membrane potential, measured using cationic fluorescent dyes such as JC-1 or TMRM in cell culture systems, is a direct readout of ETC proton pumping activity and therefore of NAD+/NADH-dependent NADH oxidation at Complex I. Research protocols using NAD+ precursor supplementation or direct NAD+ administration in aged cell culture and animal models have used membrane potential measurements as primary endpoints to assess the functional impact of NAD+ restoration on ETC activity and ATP synthetic capacity.

Research Panel: Compounds Studied Alongside NAD+

Investigators building longevity, mitochondrial biology, metabolic aging, or cellular senescence research panels frequently pair NAD+ with compounds that cover complementary aspects of the same biological systems.

5-Amino-1MQ: 5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that competes with the NAD+ salvage pathway for the nicotinamide substrate. NNMT inhibition by 5-Amino-1MQ has been studied as a strategy to increase the availability of nicotinamide for NAMPT-dependent conversion to NMN and then to NAD+, making it a natural mechanistic companion for NAD+ research designs examining the NAMPT-dependent salvage pathway. It also carries a dedicated metabolic aging and adipocyte differentiation research profile that complements NAD+’s mitochondrial function endpoints.

MOTS-C: MOTS-C is a mitochondrial-derived peptide (MDP) encoded within the 12S rRNA gene of the mitochondrial genome and studied as a regulator of AMPK activity, skeletal muscle glucose uptake, and whole-body metabolic homeostasis. Since MOTS-C’s primary research mechanism involves AMPK activation, and since AMPK and SIRT1 participate in the same positive feedback loop with NAMPT and NAD+, MOTS-C is a mechanistically coherent companion compound for NAD+ research designs examining AMPK-mediated metabolic regulation in aging and metabolic disease models.

Epithalon: Epithalon is the AEDG tetrapeptide studied for telomerase activation, telomere length maintenance, and pineal melatonin synthesis restoration in aged animal models. Since telomere shortening and mitochondrial dysfunction are both hallmarks of cellular aging that are studied in the same longevity research panels, Epithalon provides telomere biology and neuroendocrine aging coverage that complements NAD+’s mitochondrial function and sirtuin activation research profile.

GHK-Cu: GHK-Cu is the Gly-His-Lys copper-chelating tripeptide studied for gene expression regulation in aged tissue, antioxidant enzyme upregulation, and extracellular matrix remodeling. Its antioxidant and tissue-level aging biology activity complements NAD+’s intracellular metabolic and sirtuin regulation profile in multi-compound longevity research designs.

Tesamorelin: Tesamorelin is a GHRH analog studied for growth hormone axis regulation and visceral adiposity reduction in animal models. Since visceral adipose tissue accumulation is both a driver and a consequence of the metabolic dysfunction associated with age-related NAD+ decline and SIRT3 deficiency, Tesamorelin provides a GH-axis metabolic complement to NAD+ in panels examining body composition and metabolic aging endpoints.

Browse the complete longevity category for the full research compound catalog.

Legal Status of NAD+ for Research in the USA

NAD+ is a Research Use Only compound in the United States. It is not scheduled under the Controlled Substances Act and is not classified as a pharmaceutical drug or approved therapeutic agent. It is available for purchase in laboratory and preclinical research settings without a pharmaceutical license. Researchers are responsible for compliance with all applicable federal, state, and local regulations governing the purchase, handling, storage, and use of RUO compounds in their research environments.

For more background on the legal framework governing research peptides and RUO compounds in the USA, see the guide on research peptide legal status and the RUO peptides guide.

Reconstitution and Storage for Research Use

NAD+ is supplied as a lyophilized powder by Fine Research Peptides. Before use in research protocols, it is reconstituted by adding sterile bacteriostatic water slowly down the inside wall of the vial, swirling gently to dissolve without shaking. Use the peptide calculator to calculate the volume for your target research concentration.

NAD+ is available in 500mg and 1000mg vials. The reconstitution reference table below is calculated for the 1000mg vial:

Reconstitution reference volumes for NAD+ 1000mg vial:

Bacteriostatic Water Added Resulting Concentration
1 ml 1000 mg/ml
2 ml 500 mg/ml
5 ml 200 mg/ml
10 ml 100 mg/ml

Storage: Store lyophilized powder at -20 degrees C, protected from light and moisture. After reconstitution, refrigerate at 2 to 8 degrees C and use within 28 days. Avoid repeated freeze-thaw cycles. Handle with aseptic technique at all times.

For protocol guidance see the peptide reconstitution guide and the BAC water guide.

Source NAD+ for Your USA Research Program

Researchers looking to buy NAD+ for sirtuin activation research, mitochondrial function studies, PARP DNA repair investigations, cellular energy metabolism protocols, or multi-compound longevity panels can source directly from Fine Research Peptides. Every NAD+ vial is independently tested by a named USA-based third-party laboratory using HPLC and mass spectrometry before dispatch. COA batch documentation is published on the lab certifications page.

View NAD+ Pricing and Order Online

All orders ship domestically from within the USA with full order tracking. Contact the team at any time via the contact page or review common questions on the FAQs page. Quality assurance standards are detailed on the about page.

For research compound pricing context, see the peptides cost guide and the full list of research peptides and what they do.

NAD+ Research FAQs

What is NAD+ and why is it important in research?

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every living cell that plays two distinct research-relevant roles. First, it functions as an electron carrier in redox reactions, shuttling electrons into the mitochondrial electron transport chain to drive ATP synthesis through oxidative phosphorylation. Second, it serves as a required cofactor and substrate for NAD+-consuming enzymes including sirtuins (SIRT1 to SIRT7), poly-ADP-ribose polymerases (PARPs), CD38, and SARM1. Because NAD+ tissue levels decline measurably with age across multiple organs in rodent and primate models, and because this decline correlates with impaired sirtuin activity, reduced mitochondrial function, and increased DNA damage accumulation, NAD+ has become a primary research target in the longevity, metabolic aging, and mitochondrial biology research fields.

How does NAD+ activate sirtuins in research models?

Sirtuins require NAD+ as a co-substrate to perform their deacylase activity: each catalytic cycle consumes one molecule of NAD+ and produces nicotinamide, O-acetyl-ADP-ribose, and the deacetylated substrate protein. Because sirtuin activity is directly proportional to the NAD+/NADH ratio in the cell, increasing NAD+ availability raises the rate of sirtuin-catalyzed deacetylation at all sirtuin substrate proteins simultaneously. In the context of NAD+ research, this means that experimentally restoring NAD+ levels in aged or NAD+-depleted cell and animal models re-activates SIRT1 (activating PGC-1 alpha and mitochondrial biogenesis), SIRT3 (restoring mitochondrial antioxidant defense and quality control), and the other sirtuins across their respective compartments, producing a coordinated shift toward the metabolic and protective gene expression program associated with sufficient NAD+ availability.

What does NAD+ research show about mitochondrial function in aging?

Multiple preclinical studies in aged rodent models have documented that age-related NAD+ decline is associated with reduced mitochondrial mass, impaired electron transport chain complex I activity, lower mitochondrial membrane potential, and reduced ATP synthesis capacity in skeletal muscle, cardiac muscle, liver, and neural tissue. A 2025 review in npj Metabolic Health and Disease (Yusri K et al., doi:10.1038/s44324-025-00067-0) comprehensively documents the relationship between NAD+ metabolism, sirtuin-dependent mitochondrial regulation, and the mitochondrial quality control pathways including mitophagy and the UPRmt that govern mitochondrial health in aging tissue. Restoring NAD+ in aged animal models has been shown in multiple studies to partially rescue these mitochondrial function endpoints through SIRT1-dependent PGC-1 alpha activation and SIRT3-dependent restoration of mitochondrial antioxidant defense.

What is the role of SIRT3 in NAD+ mitochondrial research?

SIRT3 is the primary NAD+-dependent deacetylase inside the mitochondrial matrix and one of the most studied sirtuin targets in NAD+ longevity research. Its key substrates include SOD2 (superoxide dismutase 2), IDH2 (isocitrate dehydrogenase 2), and LCAD (long-chain acyl-CoA dehydrogenase), all of which require SIRT3-mediated deacetylation for full enzymatic activity. When SIRT3 activity falls due to insufficient NAD+, these enzymes become hyperacetylated, mitochondrial ROS production rises, fatty acid oxidation efficiency drops, and the TCA cycle is impaired. A 2025 review in Genes (Seslja K et al., doi:10.3390/genes16121497) proposes that SIRT3 loss in “driver tissues” propagates senescence-associated inflammatory signaling to distant organs, positioning SIRT3-mediated mitochondrial regulation at the center of the inflammaging hypothesis.

What is the PARP-sirtuin NAD+ competition hypothesis?

PARP1 and sirtuins compete for the same limited cellular NAD+ pool. When DNA damage accumulates in aging or genotoxically stressed cells, PARP1 is hyperactivated to repair strand breaks via ADP-ribosylation, consuming NAD+ at rates that can outpace the NAMPT-dependent salvage pathway’s ability to regenerate it. This PARP-driven NAD+ depletion directly suppresses sirtuin activity, impairing mitochondrial function and metabolic regulation. The PARP-sirtuin competition model is one of the most widely cited mechanistic frameworks in NAD+ aging research and has been tested using PARP inhibitor plus NAD+ precursor co-treatment designs in both cell culture and aged animal models to disentangle the contributions of each pathway to the metabolic phenotype of aging tissue.

What compounds are most commonly studied alongside NAD+ in longevity research panels?

The most common pairings for NAD+ in longevity and metabolic aging research panels at Fine Research Peptides are 5-Amino-1MQ for NNMT inhibition and NAD+ salvage pathway support, MOTS-C for AMPK pathway and mitochondrial-derived peptide coverage, Epithalon for telomere biology and neuroendocrine aging endpoints, and GHK-Cu for tissue-level antioxidant and gene expression regulation coverage. Tesamorelin is added to panels examining GH-axis metabolic and body composition endpoints alongside NAD+’s mitochondrial function profile. All of these compounds are available independently tested by HPLC and mass spectrometry from the longevity category.

Is NAD+ legal to buy for research in the USA?

Yes. NAD+ holds Research Use Only classification in the United States and is not scheduled under the Controlled Substances Act. It is legally available for purchase for controlled laboratory and preclinical research use without a pharmaceutical license. It is not approved for human or veterinary use. Researchers must ensure compliance with all applicable federal, state, and local regulations governing RUO compound purchase, storage, and use in their jurisdiction. See the research peptide legal status guide for a complete overview.

What purity and testing standards apply to NAD+ from Fine Research Peptides?

All NAD+ vials from Fine Research Peptides are independently analyzed by a named USA-based third-party laboratory using HPLC purity assessment and mass spectrometry molecular weight confirmation before dispatch. The stated purity is 99% or greater. Batch-specific COA documentation is published on the lab certifications page and is available before purchase, allowing researchers to review the testing data for the specific batch they are ordering. This level of pre-purchase COA transparency is standard practice for Fine Research Peptides across its full compound catalog.

How does CD38 relate to age-related NAD+ decline?

CD38 is a membrane-bound NAD+ hydrolase expressed in immune cells and across multiple tissues whose expression increases substantially with aging. The 2025 review in npj Metabolic Health and Disease (Yusri K et al., doi:10.1038/s44324-025-00067-0) identifies CD38 as a primary driver of age-related NAD+ decline, proposing that elevated CD38 activity in aging tissue accelerates NAD+ hydrolysis faster than the NAMPT-dependent salvage pathway can replenish it. Research investigating CD38 inhibition as a complementary strategy to NAD+ precursor supplementation for restoring tissue NAD+ levels in aged animals is an active area of the NAD+ longevity research literature.

Published Research Referenced

  1. Yusri K, Jose S, Vermeulen KS, Tan TCM, et al. The role of NAD+ metabolism and its modulation of mitochondria in aging and disease. npj Metabolic Health and Disease. 2025;3:26. doi:10.1038/s44324-025-00067-0. https://doi.org/10.1038/s44324-025-00067-0
  2. Seslja K, Simunic E, Soboccanec S, Podgorski II, Pinteric M, Popovic Hadzija M, Balog T, Beluzic R. SIRT3-Mediated Mitochondrial Regulation and Driver Tissues in Systemic Aging. Genes. 2025;16(12):1497. doi:10.3390/genes16121497. https://doi.org/10.3390/genes16121497 

Research Use Only

All products supplied by Fine Research Peptides are for laboratory and preclinical research use only. NAD+ is not intended for human or animal consumption and is not an approved pharmaceutical or therapeutic product. All research references cited on this page are drawn from peer-reviewed preclinical and pharmacological literature. Nothing on this page constitutes medical advice, treatment guidance, or a health benefit claim. Researchers are responsible for ensuring compliance with all applicable regulations governing the purchase, storage, and use of RUO compounds in their jurisdiction.

More insights on research peptides & lab use